196 related articles for article (PubMed ID: 19376514)
1. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
[TBL] [Abstract][Full Text] [Related]
2. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
[TBL] [Abstract][Full Text] [Related]
3. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
4. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff M; Hortobagyi GN; Hayes DF; Ambrosone CB
Clin Cancer Res; 2010 Dec; 16(24):6169-76. PubMed ID: 21169260
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract][Full Text] [Related]
7. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Walko CM; Combest AJ; Spasojevic I; Yu AY; Bhushan S; Hull JH; Hoskins J; Armstrong D; Carey L; Collicio F; Dees EC
Cancer Chemother Pharmacol; 2012 May; 69(5):1189-96. PubMed ID: 22245954
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
9. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
Ludovini V; Antognelli C; Rulli A; Foglietta J; Pistola L; Eliana R; Floriani I; Nocentini G; Tofanetti FR; Piattoni S; Minenza E; Talesa VN; Sidoni A; Tonato M; Crinò L; Gori S
BMC Cancer; 2017 Jul; 17(1):502. PubMed ID: 28747156
[TBL] [Abstract][Full Text] [Related]
10. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
[TBL] [Abstract][Full Text] [Related]
11. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
DeMichele A; Aplenc R; Botbyl J; Colligan T; Wray L; Klein-Cabral M; Foulkes A; Gimotty P; Glick J; Weber B; Stadtmauer E; Rebbeck TR
J Clin Oncol; 2005 Aug; 23(24):5552-9. PubMed ID: 16110016
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer].
Tang JH; Zhao JH; Wu JZ; Lu JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):108-13. PubMed ID: 19538885
[TBL] [Abstract][Full Text] [Related]
13. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
14. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
15. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.
Tran A; Bournerias F; Le Beller C; Mir O; Rey E; Pons G; Delahousse M; Tréluyer JM
Br J Clin Pharmacol; 2008 Feb; 65(2):279-80. PubMed ID: 17875191
[No Abstract] [Full Text] [Related]
16. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase polymorphisms influence chemotherapy response and treatment outcome in breast cancer.
Wang J; Wang T; Yin GY; Yang L; Wang ZG; Bu XB
Genet Mol Res; 2015 Sep; 14(3):11126-32. PubMed ID: 26400343
[TBL] [Abstract][Full Text] [Related]
18. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.
Sweeney C; Ambrosone CB; Joseph L; Stone A; Hutchins LF; Kadlubar FF; Coles BF
Int J Cancer; 2003 Mar; 103(6):810-4. PubMed ID: 12516103
[TBL] [Abstract][Full Text] [Related]
19. GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer.
Oliveira AL; Rodrigues FF; Santos RE; Aoki T; Rocha MN; Longui CA; Melo MB
Genet Mol Res; 2010 Jun; 9(2):1045-53. PubMed ID: 20568049
[TBL] [Abstract][Full Text] [Related]
20. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
Romero A; Martín M; Oliva B; de la Torre J; Furio V; de la Hoya M; García-Sáenz JA; Moreno A; Román JM; Diaz-Rubio E; Caldés T
Ann Oncol; 2012 Jul; 23(7):1750-6. PubMed ID: 22052985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
